0
December 11, 1996, Vol 276, No. 22 >
ARTICLE | December 11, 1996

The Heritage of Hepatitis B Vaccine FREE

R. Gordon Douglas, Jr, MD
[+] Author Affiliations

Reprints: R. Gordon Douglas, Jr, MD, Merck Vaccine Division, Merck & Co Inc, One Merck Dr, PO Box 100, Whitehouse Station, NJ 08889-0100.

A commentary on Buynak EB, Roehm RR, Tyteli AA, Bertiand AU II, Lampson GP, Hilleman MR. Vaccine against human hepatitis B. JAMA. 1976;235:2832-2834.


JAMA. 1996;276(22):1796-1798. doi:10.1001/jama.1996.03540220020011
Text Size: A A A
Published online
Article
References

Pioneering development of the plasma-derived and yeast-derived recombinant hepatitis B vaccines represents a major contribution to preventive health care of this century. Current and expanding worldwide application of hepatitis B vaccine promises to eliminate and eventually eradicate hepatitis B infection from the human population and, with it, many cases of cirrhosis and cancer of the liver.

REFERENCES

1 +
MacCallum FO.  Homologous serum jaundice . Lancet . 1947;;2:691-692.
2 +
Krugman S, Giles GP.  Infectious hepatitis: evidence for two distinctive clinical, epidemiological, and immunological types of infection . JAMA . 1967;;200:365-373.
3 +
Blumberg BS, Alter HI, Visnich S.  A 'new' antigen in leukemia sera . JAMA . 1965;;91:541-546.
4 +
Prince AM.  An antigen detected in the blood during the incubation period of serum hepatitis . Proc Natl Acad Sci U S A . 1968;;60:814-821.
5 +
Dane DS, Cameron CH, Briggs M.  Virus-like particles in serum of patients with Australia-antigen-associated hepatitis . Lancet . 1970;;1:695-698.
6 +
Buynak EB, Roehm RR, Tyteli AA, Bertiand AU II, Lampson GP, Hilleman MR.  Vaccine against human hepatitis B . JAMA . 1976;;235:2832-2834.
7 +
Hilleman MR.  Plasma-derived hepatitis B vaccine: a breakthrough in preventive medicine . In: Ellis R, ed. Hepatitis B Vaccines in Clinical Practice . New York, NY: Marcel Dekker; 1993;:17-39.
8 +
Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report . Hepatology . 1981;;1:377-385.
9 +
Francis DP, Hadler SC, Thompson SE, et al.  The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multi-center efficacy trial among homosexual men . Ann Intern Med . 1982;;97:362-386.
10 +
Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD.  Synthesis and assembly of hepatitis B virus surface antigen particles in yeast . Nature . 1982;;298:347-350.
11 +
Kane M.  Global programme for control of hepatitis B infection . Vaccine . 1995;;13( (suppl 1) ):547-549.
12 +
Maynard JE, Kane MA, Hadler SC.  Global control of hepatitis B through vaccination: role of hepatitis B vaccine in the Expanded Programme on Immunization . Rev Infect Dis . 1989;;11( (suppl 3) ):S574-S578.
13 +
Beasley RP, Huang LY.  Hepatocellular carcinoma and hepatitis B virus . Semin Liver Dis . 1984;;4:113-121.
14 +
Centers for Disease Control and Prevention.  Recommendations to prevent hepatitis B virus transmission—United States: recommendations of the Immunization Practices Advisory Committee (ACIP) . MMWR Morb Mortal Wkly Rep . 1995;;44:574-575.
15 +
Wolff JA, Malone RW, Williams W, et al.  Direct gene transfer into mouse muscle in vivo . Science . 1990;;247:1465-1468.
16 +
Moffat AS.  Exploring transgenic plants as a new vaccine source . Science . 1995;;268:658-660.
17 +
Haq TA, Mason HS, Clements JD, Arntzen CJ.  Oral immunization with a recombinant bacterial antigen produced in transgenic plants . Science . 1995;;268:714-716.
18 +
Schirmbeck R, Melber K, Kurr-Ober A, Janowicz AA, Reimann J.  Immunization with soluble hepatitis B vaccine surface protein elicits murine H-2 class 1-restricted CD8+cytotoxic T lymphocyte responses in vivo . J Immunol . 1994;;152:1110-1119.
19 +
Kovasovics-Bankowski M, Rock KL.  A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules . Science . 1995;;267:243-246.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

1 +
MacCallum FO.  Homologous serum jaundice . Lancet . 1947;;2:691-692.
2 +
Krugman S, Giles GP.  Infectious hepatitis: evidence for two distinctive clinical, epidemiological, and immunological types of infection . JAMA . 1967;;200:365-373.
3 +
Blumberg BS, Alter HI, Visnich S.  A 'new' antigen in leukemia sera . JAMA . 1965;;91:541-546.
4 +
Prince AM.  An antigen detected in the blood during the incubation period of serum hepatitis . Proc Natl Acad Sci U S A . 1968;;60:814-821.
5 +
Dane DS, Cameron CH, Briggs M.  Virus-like particles in serum of patients with Australia-antigen-associated hepatitis . Lancet . 1970;;1:695-698.
6 +
Buynak EB, Roehm RR, Tyteli AA, Bertiand AU II, Lampson GP, Hilleman MR.  Vaccine against human hepatitis B . JAMA . 1976;;235:2832-2834.
7 +
Hilleman MR.  Plasma-derived hepatitis B vaccine: a breakthrough in preventive medicine . In: Ellis R, ed. Hepatitis B Vaccines in Clinical Practice . New York, NY: Marcel Dekker; 1993;:17-39.
8 +
Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report . Hepatology . 1981;;1:377-385.
9 +
Francis DP, Hadler SC, Thompson SE, et al.  The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multi-center efficacy trial among homosexual men . Ann Intern Med . 1982;;97:362-386.
10 +
Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD.  Synthesis and assembly of hepatitis B virus surface antigen particles in yeast . Nature . 1982;;298:347-350.
11 +
Kane M.  Global programme for control of hepatitis B infection . Vaccine . 1995;;13( (suppl 1) ):547-549.
12 +
Maynard JE, Kane MA, Hadler SC.  Global control of hepatitis B through vaccination: role of hepatitis B vaccine in the Expanded Programme on Immunization . Rev Infect Dis . 1989;;11( (suppl 3) ):S574-S578.
13 +
Beasley RP, Huang LY.  Hepatocellular carcinoma and hepatitis B virus . Semin Liver Dis . 1984;;4:113-121.
14 +
Centers for Disease Control and Prevention.  Recommendations to prevent hepatitis B virus transmission—United States: recommendations of the Immunization Practices Advisory Committee (ACIP) . MMWR Morb Mortal Wkly Rep . 1995;;44:574-575.
15 +
Wolff JA, Malone RW, Williams W, et al.  Direct gene transfer into mouse muscle in vivo . Science . 1990;;247:1465-1468.
16 +
Moffat AS.  Exploring transgenic plants as a new vaccine source . Science . 1995;;268:658-660.
17 +
Haq TA, Mason HS, Clements JD, Arntzen CJ.  Oral immunization with a recombinant bacterial antigen produced in transgenic plants . Science . 1995;;268:714-716.
18 +
Schirmbeck R, Melber K, Kurr-Ober A, Janowicz AA, Reimann J.  Immunization with soluble hepatitis B vaccine surface protein elicits murine H-2 class 1-restricted CD8+cytotoxic T lymphocyte responses in vivo . J Immunol . 1994;;152:1110-1119.
19 +
Kovasovics-Bankowski M, Rock KL.  A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules . Science . 1995;;267:243-246.

Letters

Submit a Letter
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2012 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems